[USE CASE] A biopharmaceutical company wanted to hear what was being said about one of their specific brands and understand what alternative treatments were being discussed. By analyzing their patient conversations, Authenticx found opportunities to train agents, improve call guides, and understand patient sentiment around alternatives. The company: ✔️ Highlighted best practices using talking points ✔️ Performed call exercises with agents, such as role playing ✔️ Leveraged actual audio montages to surface common topics and themes Draw actionable insights to prepare for competitor messaging today ➡️ https://hubs.li/Q02V1xZZ0 #ListenAtScale #CompetitorMessaging #CallCenterOperations
Authenticx’s Post
More Relevant Posts
-
Thoughts on this? >> A primer on brand-name prescription drug contracting >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical
A primer on brand-name prescription drug contracting – Healthcare Economist
https://www.healthcare-economist.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> A primer on brand-name prescription drug contracting >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #pharmaceutical #biotech
A primer on brand-name prescription drug contracting – Healthcare Economist
https://www.healthcare-economist.com
-
The G-BA's revamped pharmaceutical assessment rules promise enhanced clarity and efficiency, driving precise health economic models and improved market access strategies. Effective April 2024, these changes streamline evaluations for better patient outcomes in Germany's healthcare system. #RegulatoryAgencies #Pharma #HealthcareInnovation #MarketAccessToday #MarketAccess
G-BA Revamps Pharmaceutical Assessment Rules for Enhanced Clarity and Efficiency
https://marketaccesstoday.com
-
Thoughts on this? >> Expanding our Definitions of Out-of-Pocket Costs: Three Imperatives for Biopharmaceutical Manufacturers >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing
Expanding our Definitions of Out-of-Pocket Costs: Three Imperatives for Biopharmaceutical Manufacturers
drugchannels.net
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Expanding our Definitions of Out-of-Pocket Costs: Three Imperatives for Biopharmaceutical Manufacturers >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #healthcare #biotech
Expanding our Definitions of Out-of-Pocket Costs: Three Imperatives for Biopharmaceutical Manufacturers
drugchannels.net
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> As MFP Approaches, Transparency Is More Important Than Ever >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #productmarketing #pharmaceutical #biotech
As MFP Approaches, Transparency Is More Important Than Ever
drugchannels.net
-
Thoughts on this? >> When Payers Become Producers: Inside the PBM Private-Labeling Trend >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #biotech #pharma #pharmaceutical
When Payers Become Producers: Inside the PBM Private-Labeling Trend
drugchannels.net
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead (rerun) >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #biotech #pharmaceutical
The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead (rerun)
drugchannels.net
-
Lockton Companies Commercial P&C | Real Estate Development | Private Equity-M&A-Transaction Liability | Energy | Manufacturing | Proud Buffalo, NY Native
Those of you involved in life sciences will find our most recent Market Update informative, if not an excellent preface to a candid conversation about your companies insurance program. We understand that the life sciences industry is different, that a customized program is crucial in protecting businesses involved in pharmaceutical, research and development, medical device manufacturing, and human clinical trials. When it comes to managing risk it’s the quality of our thinking and our proactive approach that makes us different.
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> When Payers Become Producers: Inside the PBM Private-Labeling Trend >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #biotech #pharmaceutical #pharma
When Payers Become Producers: Inside the PBM Private-Labeling Trend
drugchannels.net
